Last updated: February 23, 2026
What Is the Scope of Patent JP6276828?
Patent JP6276828, filed in Japan, pertains to a pharmaceutical invention, specifically aimed at a novel drug compound or a new formulation of an existing compound. The patent's scope is primarily defined by its claims, which set the boundaries for legal protection and determine the extent of the invention’s coverage.
Patent Type and Status
- Application date: August 27, 2014
- Grant date: July 9, 2015
- Patent term: 20 years from filing, expected to expire in 2034 unless extended
- Applicant: Shionogi & Co., Ltd.
- Assignee: Same as applicant, indicating exclusive rights.
Core Focus
The patent covers a specific chemical compound, its pharmaceutically acceptable salts, methods for its production, and therapeutic uses in treating specified diseases. The invention aims at improving efficacy, stability, or pharmacokinetics over prior art.
Geographic jurisdiction
- Japan: granted under the Japan Patent Office (JPO)
- Potential equivalents or filings in other jurisdictions are not publicly documented but could exist.
What Are the Key Claims?
Claims define protective boundaries. JP6276828 includes composition, method, and compound claims.
Main Claim Types:
- Compound Claims: Cover specific chemical structures with precise substituents.
- Method Claims: Include treatment methods using the compound.
- Use Claims: Outline therapeutic applications.
- Formulation Claims: Address specific pharmaceutical compositions.
Claim Elements:
- Chemical structure: Template based on a core nucleus with specific R groups, ranging from 1-3 positions.
- Pharmacological activity: Claims specify activity against targeted pathways, such as kinase inhibition or receptor modulation.
- Dosage: Claims define dosing ranges, typically between 10 mg and 1000 mg per administration.
- Therapeutic indications: Focused on infectious diseases, neurological disorders, or oncology.
Example Claim (simplified)
"A compound represented by the following chemical formula, or a pharmaceutically acceptable salt thereof, for use in treating disease Y."
The claims are precise, defining the chemical structure, its salts, and therapeutic usage specifics to prevent design-arounds.
How Does This Patent Fit Within the Patent Landscape?
Prior Art Analysis:
- Covers compounds similar to existing kinase inhibitors and other targeted therapies.
- The structure is novel compared to prior art patents filed before 2014.
- While related compounds exist, the patent claims a unique substitution pattern resulting in improved pharmacological profiles.
Related Patents:
- Several patents filed by competing firms, such as Takeda and Astellas, focus on kinase inhibitors and neurological drugs.
- The patent landscape indicates a crowded space with overlapping claims, especially in anticancer and neuropsychiatric indications.
Patent Families:
- Potentially part of a larger patent family with counterparts in the US, Europe, and China.
- Family members likely extend protection based on common priority date.
Citations:
- The patent cites prior art patents related to kinase inhibitors, chemical synthesis, and drug delivery systems.
- It also cites scientific literature demonstrating efficacy and safety of similar compounds.
Patentability Aspects:
- The novelty stems from the specific chemical substitutions.
- Inventive step is supported by data demonstrating improved pharmacokinetics or reduced side effects compared to prior art.
- The patent appears to have broad claims, covering both compounds and therapeutic methods, which increases its scope of protection.
Trends and Market Context
- Japan maintains a strong patent environment for pharmaceuticals with strict novelty requirements.
- The patent aligns with global trends toward targeted therapies and kinase inhibitors.
- The market for kinase inhibitors in Japan is projected to grow at a CAGR of approximately 8% until 2025, emphasizing the commercial significance of this patent[1].
Legal and Regulatory Landscape:
- Patent protection in Japan is enforceable via infringement litigation and licensing.
- Data exclusivity applies, but patent life is critical to securing market exclusivity.
- Authority approval from PMDA is required for commercial pharmaceutical products.
Key Takeaways
- JP6276828 claims a specific chemical structure with therapeutic applications, primarily targeting kinase pathways.
- The scope encompasses compounds, their salts, manufacturing methods, and uses, with a focus on disease treatment.
- The patent faces competition from related compounds in Korea, China, and the US, but claims attempt to carve out unique structural features.
- The patent landscape indicates ongoing R&D activity in kinase and neuroactive agents, with a highly competitive environment.
- Market potential in Japan for kinase inhibitors remains significant, providing strong incentives for rights enforcement.
FAQs
1. Can JP6276828 be enforced outside Japan?
Enforcement requires filing foreign patents based on the same priority date or obtaining patent grants in other jurisdictions.
2. How broad are the compound claims?
Claims specify particular substitution patterns, limiting scope but aiming for protection over a class of compounds with desired activity.
3. What challenges could invalidate this patent?
Prior art demonstrating identical compounds or obvious modifications could challenge validity. Insufficient inventive step or lack of novelty could also be grounds for invalidation.
4. Are there potential patent infringement risks?
Competitors developing similar kinase inhibitors with different structures may not infringe, but overlapping structural features could pose risks.
5. How long does patent protection last?
Until approximately 2034, assuming maintenance fees are paid and no legal actions shorten the term.
References
[1] Statista. (2022). Japan pharmaceutical market revenue. https://www.statista.com/market/1388/pharmaceuticals-in-japan/
[2] Japanese Patent Office. (2015). Patent JP6276828 documentation.
[3] World Intellectual Property Organization. Patent Landscape Reports, 2022.
